IL272291B2 - Dual mode radiotracer and -therapeutics - Google Patents

Dual mode radiotracer and -therapeutics

Info

Publication number
IL272291B2
IL272291B2 IL272291A IL27229120A IL272291B2 IL 272291 B2 IL272291 B2 IL 272291B2 IL 272291 A IL272291 A IL 272291A IL 27229120 A IL27229120 A IL 27229120A IL 272291 B2 IL272291 B2 IL 272291B2
Authority
IL
Israel
Prior art keywords
psma
sifa
pct
compound
bond
Prior art date
Application number
IL272291A
Other languages
English (en)
Hebrew (he)
Other versions
IL272291A (en
IL272291B1 (en
Original Assignee
Univ Muenchen Tech
Technische Univ Munchen Klinikum Rechts Der Isar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech, Technische Univ Munchen Klinikum Rechts Der Isar filed Critical Univ Muenchen Tech
Publication of IL272291A publication Critical patent/IL272291A/en
Publication of IL272291B1 publication Critical patent/IL272291B1/en
Publication of IL272291B2 publication Critical patent/IL272291B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
IL272291A 2017-07-28 2018-07-30 Dual mode radiotracer and -therapeutics IL272291B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17183795 2017-07-28
PCT/EP2018/070533 WO2019020831A1 (en) 2017-07-28 2018-07-30 AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES

Publications (3)

Publication Number Publication Date
IL272291A IL272291A (en) 2020-03-31
IL272291B1 IL272291B1 (en) 2025-02-01
IL272291B2 true IL272291B2 (en) 2025-06-01

Family

ID=59501286

Family Applications (2)

Application Number Title Priority Date Filing Date
IL318092A IL318092A (en) 2017-07-28 2018-07-30 Dual mode radiotracer and –therapeutics
IL272291A IL272291B2 (en) 2017-07-28 2018-07-30 Dual mode radiotracer and -therapeutics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL318092A IL318092A (en) 2017-07-28 2018-07-30 Dual mode radiotracer and –therapeutics

Country Status (20)

Country Link
US (3) US11413360B2 (enExample)
EP (3) EP4000640A1 (enExample)
JP (2) JP7059372B2 (enExample)
KR (2) KR20240027896A (enExample)
CN (1) CN111132700B (enExample)
AU (2) AU2018308699B2 (enExample)
BR (1) BR112020001785A2 (enExample)
CA (1) CA3071315A1 (enExample)
DK (1) DK3658194T3 (enExample)
EA (1) EA202090370A1 (enExample)
ES (1) ES3011272T3 (enExample)
FI (1) FI3658194T3 (enExample)
HU (1) HUE070098T2 (enExample)
IL (2) IL318092A (enExample)
MX (2) MX2020000352A (enExample)
PL (1) PL3658194T3 (enExample)
PT (1) PT3658194T (enExample)
SG (1) SG11202000725WA (enExample)
WO (1) WO2019020831A1 (enExample)
ZA (1) ZA202000467B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019020831A1 (en) * 2017-07-28 2019-01-31 Technische Universität München AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES
JP7528100B2 (ja) * 2019-01-30 2024-08-05 テクニシェ ユニバーシタット ミュンヘン Psma結合デュアルモード放射性トレーサーおよび療法
CN113677375B (zh) * 2019-01-30 2024-07-23 慕尼黑工业大学 氟化硅受体取代的放射性药物及其前体
EA202192045A1 (ru) * 2019-01-30 2021-10-27 Технише Универзитет Мюнхен Средства для диагностической визуализации ракового заболевания
CN112168978B (zh) * 2019-07-03 2022-01-11 北京大学 一种抗体偶联药物及其药物组合物与应用
WO2021086917A1 (en) * 2019-10-29 2021-05-06 The Cleveland Clinic Foundation Psma-targeting imaging agents
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
EP4185336A1 (en) 2020-07-23 2023-05-31 Technische Universität München Silicon-containing ligand compounds
MX2023002614A (es) 2020-09-03 2023-07-07 Curium Us Llc Radiomarcado y formulacion para escalado de 64cu-dotatate.
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
JP2024507343A (ja) * 2021-02-15 2024-02-19 テクニシェ ユニバーシタット ミュンヘン デュアルモード放射性トレーサーおよびその療法
MX2023013485A (es) * 2021-05-14 2023-12-07 Univ Muenchen Tech Radiofarmacos ligandos del receptor de la somatostatina y precursores de los mismos.
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
WO2023012282A1 (en) * 2021-08-05 2023-02-09 Technische Universität München Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
CN114671806B (zh) * 2022-04-08 2024-03-01 上海如絮生物科技有限公司 一种亲水性吡啶衍生物、中间体、其制备方法及应用
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
KR20250049308A (ko) 2022-07-29 2025-04-11 테크니쉐 유니베르시테트 뮌헨 방사성 의약품용 규소계 불화물 수용기
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
CN119907695A (zh) * 2022-09-20 2025-04-29 慕尼黑工业大学 用于成像和靶向放疗的新型小胃泌素衍生的胆囊收缩素2受体结合分子
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途
AU2023379454A1 (en) * 2022-11-14 2025-05-29 Aktis Oncology, Inc. Decreased retention of miniproteins in kidney
WO2025072791A2 (en) 2023-09-29 2025-04-03 Aktis Oncology, Inc. Miniproteins, conjugates & uses thereof
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102626522A (zh) * 2012-04-12 2012-08-08 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7384394A (en) * 1993-06-30 1995-01-24 Akzo Nobel N.V. Chelating compounds
EP1420831A1 (en) 2001-07-27 2004-05-26 Targesome, Inc. Lipid constructs as therapeutic and imaging agents
CA2949936C (en) * 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
CA2982269C (en) * 2015-05-26 2023-12-05 The Regents Of The University Of California Heteroaromatic silicon-fluoride-acceptors useful for 18f labeling of molecules and biomolecules, and methods of preparing same
WO2019020831A1 (en) 2017-07-28 2019-01-31 Technische Universität München AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES
EP4008359B1 (en) * 2017-12-11 2024-09-11 Technische Universität München Psma ligands for imaging and endoradiotherapy
JP7528100B2 (ja) 2019-01-30 2024-08-05 テクニシェ ユニバーシタット ミュンヘン Psma結合デュアルモード放射性トレーサーおよび療法
EA202192045A1 (ru) 2019-01-30 2021-10-27 Технише Универзитет Мюнхен Средства для диагностической визуализации ракового заболевания

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102626522A (zh) * 2012-04-12 2012-08-08 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
S. LITAU ET AL,, NEXT GENERATION OF SIFA LIN -BASED TATE DERIVATIVES FOR PET IMAGING OF SSTR-POSITIVE TUMORS: INFLUENCE OF MOLECULAR DESIGN ON IN VITRO SSTR BINDING AND IN VIVO PHARMACOKINETICS, 16 December 2015 (2015-12-16) *
SIMON LINDNER ET AL,, SYNTHESIS AND IN VITRO AND IN VIVO EVALUATION OF SIFA-TAGGED BOMBESIN AND RGD PEPTIDES AS TUMOR IMAGING PROBES FOR POSITRON EMISSION TOMOGRAPHY, 16 April 2014 (2014-04-16) *
VADIM BERNARD-GAUTHIER ET AL,, FROM UNORTHODOX TO ESTABLISHED: THE CURRENT STATUS OF 18 F-TRIFLUOROBORATE- AND 18 F-SIFA-BASED RADIOPHARMACEUTICALS IN PET NUCLEAR IMAGING, 17 February 2016 (2016-02-17) *

Also Published As

Publication number Publication date
US20200197545A1 (en) 2020-06-25
DK3658194T3 (da) 2025-02-17
PT3658194T (pt) 2025-02-13
JP7059372B2 (ja) 2022-04-25
JP2022101601A (ja) 2022-07-06
IL272291A (en) 2020-03-31
PL3658194T3 (pl) 2025-09-15
EP4424378A2 (en) 2024-09-04
CN111132700B (zh) 2022-12-13
ZA202000467B (en) 2022-06-29
US20220370649A1 (en) 2022-11-24
KR102752620B1 (ko) 2025-01-10
EA202090370A1 (ru) 2020-05-25
CA3071315A1 (en) 2019-01-31
EP3658194B1 (en) 2024-11-27
KR20200064057A (ko) 2020-06-05
AU2018308699B2 (en) 2023-11-30
IL318092A (en) 2025-02-01
SG11202000725WA (en) 2020-02-27
WO2019020831A1 (en) 2019-01-31
BR112020001785A2 (pt) 2020-09-29
AU2024200440A1 (en) 2024-02-08
EP4000640A1 (en) 2022-05-25
MX2020000352A (es) 2020-08-17
EP4424378A3 (en) 2024-12-11
AU2024200440B2 (en) 2025-04-24
US12390540B2 (en) 2025-08-19
IL272291B1 (en) 2025-02-01
MX2023007914A (es) 2023-07-13
FI3658194T3 (fi) 2025-02-28
US12453787B2 (en) 2025-10-28
EP3658194A1 (en) 2020-06-03
US11413360B2 (en) 2022-08-16
AU2018308699A1 (en) 2020-01-23
CN111132700A (zh) 2020-05-08
ES3011272T3 (en) 2025-04-07
JP2020528461A (ja) 2020-09-24
HUE070098T2 (hu) 2025-05-28
KR20240027896A (ko) 2024-03-04
US20250121102A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
AU2024200440B2 (en) Dual mode radiotracer and -therapeutics
JP7549585B2 (ja) がん診断用画像化剤
CA3207132A1 (en) Dual mode radiotracer and -therapeutics
CA3211030A1 (en) Dual mode radiotracer and therapeutics
WO2022018264A1 (en) Silicon-containing ligand compounds
JP2024517971A (ja) 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体
HK40022705B (en) Dual mode radiotracer and -therapeutics
HK40022705A (en) Dual mode radiotracer and -therapeutics
EA046402B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство